OBJECTIVE: Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease and mortality. Lipid-lowering therapy is reportedly underused in patients with RA. Longitudinal cohort studies comparing use of lipid-lowering medications in patients with RA versus the general population are lacking. METHODS: Cardiovascular risk factors, lipid measures, and use of lipid-lowering agents were assessed in a population-based inception cohort of patients with RA and a cohort of non-RA subjects followed from January 1, 1988, to December 31, 2008. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII) guidelines were assessed at the time of each lipid measure throughout followup. Time from meeting guidelines to initiation of lipid-lowering agents was assessed using Kaplan-Meier methods. RESULTS: The study population included 412 RA and 438 non-RA patients with ≥ 1 lipid measure during followup and no prior use of lipid-lowering agents. Rates of lipid testing were lower among patients with RA compared to non-RA subjects. Among patients who met NCEP ATPIII criteria for lipid-lowering therapy (n = 106 RA; n = 120 non-RA), only 27% of RA and 26% of non-RA subjects initiated lipid-lowering agents within 2 years of meeting the guidelines for initiation. CONCLUSION: There was substantial undertreatment in both the RA and the non-RA cohorts who met NCEP ATPIII criteria for initiation of lipid-lowering agents. Patients with RA did not have as frequent lipid testing as individuals in the general population.
OBJECTIVE:Rheumatoid arthritis (RA) is associated with an increased risk of cardiovascular disease and mortality. Lipid-lowering therapy is reportedly underused in patients with RA. Longitudinal cohort studies comparing use of lipid-lowering medications in patients with RA versus the general population are lacking. METHODS: Cardiovascular risk factors, lipid measures, and use of lipid-lowering agents were assessed in a population-based inception cohort of patients with RA and a cohort of non-RA subjects followed from January 1, 1988, to December 31, 2008. The National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATPIII) guidelines were assessed at the time of each lipid measure throughout followup. Time from meeting guidelines to initiation of lipid-lowering agents was assessed using Kaplan-Meier methods. RESULTS: The study population included 412 RA and 438 non-RA patients with ≥ 1 lipid measure during followup and no prior use of lipid-lowering agents. Rates of lipid testing were lower among patients with RA compared to non-RA subjects. Among patients who met NCEP ATPIII criteria for lipid-lowering therapy (n = 106 RA; n = 120 non-RA), only 27% of RA and 26% of non-RA subjects initiated lipid-lowering agents within 2 years of meeting the guidelines for initiation. CONCLUSION: There was substantial undertreatment in both the RA and the non-RA cohorts who met NCEP ATPIII criteria for initiation of lipid-lowering agents. Patients with RA did not have as frequent lipid testing as individuals in the general population.
Authors: Jesper Lindhardsen; Ole Ahlehoff; Gunnar Hilmar Gislason; Ole Rintek Madsen; Jonas Bjerring Olesen; Christian Torp-Pedersen; Peter Riis Hansen Journal: Ann Rheum Dis Date: 2012-03-08 Impact factor: 19.103
Authors: M Boers; M T Nurmohamed; C J A Doelman; L R Lard; A C Verhoeven; A E Voskuyl; T W J Huizinga; R J van de Stadt; B A C Dijkmans; Sj van der Linden Journal: Ann Rheum Dis Date: 2003-09 Impact factor: 19.103
Authors: Hilal Maradit Kremers; Michelle Bidaut-Russell; Christopher G Scott; Megan S Reinalda; Alan R Zinsmeister; Sherine E Gabriel Journal: J Rheumatol Date: 2003-09 Impact factor: 4.666
Authors: Rachel H Mackey; Lewis H Kuller; Kevin D Deane; Brian T Walitt; Yue-Fang Chang; V Michael Holers; William H Robinson; Russell P Tracy; Mark A Hlatky; Charles B Eaton; Simin Liu; Matthew S Freiberg; Mehret Birru Talabi; Erik B Schelbert; Larry W Moreland Journal: Arthritis Rheumatol Date: 2015-09 Impact factor: 10.995
Authors: Jorge A Zamora-Legoff; Elena Myasoedova; Eric L Matteson; Sara J Achenbach; Cynthia S Crowson Journal: Clin Rheumatol Date: 2016-06-22 Impact factor: 2.980